Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV)

NCT05435027 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

342

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2

Interventions

DRUG: GRT-R912, samRNA-Spikebeta-TCE11
DRUG: GRT-R914, samRNA-Spikebeta-TCE9
DRUG: GRT-R918, samRNA-SpikeOmicron-N-TCE11

Sponsor

Gritstone bio, Inc.